Last Update 06 Aug 26
Fair value Decreased 43%CORT: Elevated Expectations Around Cushing’s Decision Will Shape Bearish Risk Outlook
Corcept Therapeutics' updated fair value estimate has moved from $88 to $50. This reflects analysts' wider range of views after several firms sharply raised their price targets into the $95 to $165 band, based on stronger recent results, expanded 2026 revenue guidance, and growing confidence in Lifyorli, Korlym, and the broader pipeline. These factors are balanced against more cautious assumptions on execution and valuation risk.
Analyst Commentary
Recent Street research on Corcept Therapeutics shows a split in sentiment. Some firms highlight stronger recent results, higher 2026 revenue guidance, and expanding opportunities for Lifyorli, Korlym, and the broader pipeline. At the same time, several bearish analysts are pushing back on how much success is already reflected in the current valuation and how smoothly execution might play out.
On the more constructive side, multiple price target increases reference Corcept Therapeutics delivering Q2 diluted EPS of $0.36 on revenue of $256.1m versus Street estimates of $0.02 and $220m. The company is guiding to 2026 total revenue of $1.1b to $1.2b, up from a prior range of $950m to $1.05b. Bulls also point to Lifyorli's early ovarian cancer uptake, Korlym's sales recovery, and the potential for relacorilant in patients with hypercortisolism if the resubmitted new drug application is successful.
Several firms describe Corcept Therapeutics as transitioning into a multi product franchise, with oncology now part of the story. They also flag what they see as underappreciated potential for Lifyorli and the possibility of additional indications if current programs progress. Supportive research notes tie these points to higher price targets and ratings upgrades, with some firms expressing increased confidence that upcoming regulatory and clinical updates could be positive catalysts.
Bearish Takeaways
- Bearish analysts argue that Corcept Therapeutics' roughly $10b valuation already prices in a successful Cushing's NDA resubmission, favorable legal outcomes, and continued strength in existing products. In their view, this leaves limited room for setbacks without pressure on the stock.
- Some research highlights concern that the current valuation assumes limited competitive impact from generic mifepristone and strong cash conversion. These assumptions could prove difficult to meet if competition intensifies or if costs rise as the pipeline advances.
- There is caution that expectations for Lifyorli and the broader oncology opportunity may be running ahead of what has been fully validated. This could create execution risk if uptake or trial results do not match current enthusiasm.
- At least one bearish analyst has moved to an Underperform stance with a $50 price target, framing current pricing as already baking in multiple favorable outcomes across regulatory, competitive, and pipeline fronts. They describe this as a demanding setup for future growth delivery.
What’s in the News for Corcept Therapeutics
- Corcept Therapeutics reported second quarter financial results, with performance described as strong in its oncology and Cushing’s syndrome businesses and with Lifyorli gaining FDA approval and demand described as accelerating. The company also provided a broad corporate update. Source: Corcept Therapeutics corporate announcement.
- The company raised its 2026 revenue guidance to a range of US$1.1b to US$1.2b and cited continued strength across its businesses in connection with this outlook. Source: Company guidance update.
- Corcept Therapeutics resubmitted its New Drug Application to the FDA for relacorilant in Cushing’s syndrome, including additional analyses requested by the agency and based on data from the GRACE and GRADIENT trials and related studies. The company expects a six month review period for this resubmission. Source: Company product announcement.
- Lifyorli, used with nab paclitaxel, received FDA approval in March 2026 for adults with platinum resistant ovarian cancer and is included in NCCN Guidelines as a preferred regimen. New overall survival data from the Phase 3 ROSELLA trial were presented at ASCO 2026, with the company reporting a 35% reduction in risk of death versus nab paclitaxel alone. Source: ASCO 2026 presentation and company announcement.
- Corcept Therapeutics was dropped from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index. The company also reported that the U.S. Department of Justice and several states declined to intervene in a civil qui tam action related to Korlym, and Corcept plans to continue defending the case. Source: Index and legal event filings.
Valuation Changes for Corcept Therapeutics
- Fair value has fallen from $88 to $50. This reflects a lower central estimate alongside a wider range of analyst views on Corcept Therapeutics.
- The discount rate is effectively unchanged at 7.108%. This suggests the required return assumption used in the valuation has stayed stable.
- Revenue growth has been revised from 26.08% to 23.30%. Expectations remain elevated but now assume a more moderate growth profile.
- Profit margin has risen from 31.04% to 41.45%. The updated model assumes Corcept Therapeutics could retain more earnings on each dollar of future sales.
- The future P/E has moved from 25.54x to 11.04x. The new fair value estimate now rests on a lower earnings multiple.
Catalysts
About Corcept Therapeutics
Corcept Therapeutics develops proprietary selective cortisol modulators to treat endocrine, oncologic, neurologic and metabolic diseases.
What are the underlying business or industry changes driving this perspective?
- Although relacorilant is approaching an FDA decision in hypercortisolism alongside growing physician recognition that the disorder is far more prevalent than historically assumed, any delay in approval, label constraints or slower than expected conversion from Korlym could mute the anticipated step-up in prescription volume and defer revenue acceleration.
- Despite expanding its specialty pharmacy network to relieve current fulfillment bottlenecks and support thousands of additional patients, execution risk in transitioning pharmacies and coordinating multiple distributors could prolong supply inefficiencies and increase operating costs, limiting near term margin expansion and earnings growth.
- While the oncology portfolio targets large unmet needs across ovarian, endometrial, cervical and pancreatic cancers with guideline-enabling studies, negative or merely incremental data from ROSELLA follow-ons, BELLA or other trials would undermine the rationale for broad cortisol-modulation use in solid tumors and cap future oncology revenue and returns on R&D spend.
- Although large disease populations in MASH and ALS offer significant optionality for miricorilant and dazucorilant, the long and competitive development timelines, potential Phase III failures and the need for sizable commercialization investment could weigh on net margins and limit the contribution of these programs to medium term earnings.
- Even as cortisol modulation gains scientific validation and Corcept advances multiple NDAs and global filings, the breadth of parallel late stage programs raises the risk of budget strain, prioritization missteps and post approval commercialization complexity, which could pressure SG&A, dilute returns on invested capital and dampen long run earnings leverage.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Corcept Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Corcept Therapeutics's revenue will grow by 23.3% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 6.5% today to 41.4% in 3 years time.
- The bearish analysts expect earnings to reach $645.5 million (and earnings per share of $4.58) by about August 2029, up from $54.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.8 billion.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 11.1x on those 2029 earnings, down from 220.5x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 15.5x.
- The bearish analysts expect the number of shares outstanding to grow by 2.59% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Net income has declined materially despite strong top line growth, with third quarter 2025 revenue rising to $207.6 million while net income fell to $19.7 million compared to $47.2 million last year. This suggests that structurally higher R&D and SG&A required to support an expanded pipeline and multiple launches could compress net margins and slow earnings growth over the long term.
- The adverse patent litigation ruling against Teva is still under appeal and could be decided at any time. If Corcept fails to block generic Korlym competition before 2037, accelerating migration to lower priced authorized generics and potential entry of additional generics would pressure pricing power, limiting revenue growth and eroding gross margins over time.
- The investment heavy strategy of running parallel late stage programs in hypercortisolism, multiple solid tumors, MASH and ALS, combined with increasing SG&A to build larger commercial organizations, risks outpacing the revenue contribution from any single successful program. This could drive sustained operating expense growth faster than sales and constrain long run earnings expansion.
- Corcept’s oncology thesis relies on cortisol receptor antagonism becoming guideline enabling across a broad range of solid tumors. If forthcoming data from ROSELLA survival readouts, BELLA, pancreatic and gynecologic cancer studies or immunotherapy combinations prove only modest or inconsistent, long term adoption could fall short of expectations, capping oncology revenue potential and limiting future operating leverage.
- The long duration and competitive nature of MASH and ALS markets means that delays, regulatory setbacks or failure of miricorilant and dazucorilant to replicate early promising data in larger Phase IIb and Phase III trials could significantly reduce the expected contribution from these large indications. This could leave the company more dependent on a narrower product base and constrain diversified revenue and earnings growth.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Corcept Therapeutics is $50.0, which represents up to two standard deviations below the consensus price target of $135.25. This valuation is based on what can be assumed as the expectations of Corcept Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $165.0, and the most bearish reporting a price target of just $50.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $645.5 million, and it would be trading on a PE ratio of 11.1x, assuming you use a discount rate of 7.1%.
- Given the current share price of $110.69, the analyst price target of $50.0 is 121.4% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Corcept Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
